Navigation Links
SV Life Sciences Appoints Veteran Diagnostics Professional Dr. Heiner Dreismann as Venture Partner

BOSTON, SAN FRANCISCO and LONDON, Oct. 5, 2011 /PRNewswire/ --SV Life Sciences ("SVLS") today announced the appointment of Dr. Heiner Dreismann, as Venture Partner. Dr. Dreismann joins SVLS with more than 26 years of experience in the health care industry.

"We are very excited to welcome Dr. Dreismann to SVLS," said Lutz Giebel, SVLS Managing Partner. "Dr. Dreismann will join our biotechnology team and focus on investments in the diagnostics space. We believe favorable market dynamics make this a perfect time to expand our capabilities in this area and Dr. Dreismann's knowledge and expertise will be invaluable assets as we do so."

Dr. Dreismann is highly regarded in the healthcare industry with over 26 years of experience. He serves on the boards of several innovative public and private diagnostic companies. Dreismann completed a successful career at Roche Group from 1985 to 2006 where he held several senior positions including President and CEO of Roche Molecular Systems, Head of Global Business Development at Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee.

"Joining SVLS is a tremendous opportunity for me to bring my expertise in diagnostics and life sciences to venture capital investing," said Dreismann. "SVLS has a stellar market reputation and I look forward to helping grow the diagnostics vertical in the firm's portfolio."

Dr. Dreismann earned a Master of Science in biology and a Doctor of Philosophy in microbiology/molecular biology from Westfaelische Wilhelms University in Muenster, Germany. He conducted his Post-Doctoral studies in microbial genetics at the Centre d'Etudes Nucleaires de Saclay, France. Dr. Dreismann is an active member of the in vitro diagnostics (IVD) industry community and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique.

Dr. Dreismann is a member of SVLS' team of 35 professionals organized according to experience and specialization into three practice areas: Biotechnology / Biopharmaceuticals; Medical Devices / Instrumentation; and Healthcare Services. These individuals' diverse and complimentary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds.

About SV Life Sciences

SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds with approximately $2 billion of capital under management. The Firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company's website at


Denise Marks
Partner and CFO
SV Life Sciences
T: +1 617 367 8100
Email :

Lutz Giebel, PhD
Managing Partner
SV Life Sciences
T: +1 650 571 8200

Roland Tomforde
Managing Director
Broadgate Consultants
T: +1 212 232 2222

SOURCE SV Life Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: ... Rugen Therapeutics, a start-up  biotechnology company focused on ... disorders and funded by the F-Prime Biomedical Research ... into an exclusive collaboration to support the discovery ... Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 USP 800 applies to all ... pharmacists, pharmacy technicians, nurses, physicians, physician assistants, home ... also covers all entities which store, prepare, transport, ... healthcare institutions, patient treatment clinics, physicians, practice facilities, ... --> What is the purpose of ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... ... 26, 2015 , ... Ministers, senior government and UN agencies, ... Centres of Excellence, and public R&D institutions, civil societies and other partners gathered ... 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based drug ... their sobriety and show through pictures what a positive difference it makes. The ... with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and ... Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Beddit® has ... Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ that ... understand how well you slept. The SleepScore is created by a proprietary algorithm. Beddit ...
Breaking Medicine News(10 mins):